human osteosarcoma mg63 cells  (ATCC)

Journal: RSC Advances

Article Title: Replicating the post-chemotherapy tumor microenvironment via biomimetic scaffolds to regulate MSC differentiation

doi: 10.1039/d6ra01031h

Figure Lengend Snippet: Biological characterizations of DOX-MSNCaP@PLGA-collagen and PLGA-collagen constructs. The accumulate release of DOX from DOX-MSNCaP@PLGA-collagen in PBS buffer with different pH (A). Cytotoxic assessment of MG63 cells after being cultured in scaffolds via live and dead staining. Cells were seed in the meshes and incubated in DMEM at pH 7.4 or pH 6.5 (B). Fluorescence microscopic observation on the intracellular distribution of DOX in MG63 cells after incubation with DOX-MSNCaP@PLGA-collagen scaffolds for 12 hours. Cell nucleus was represented blue fluorescence; DOX was represented red fluorescence; actin cytoskeleton was represented green fluorescence (C). DNA laddering analysis on the severity of DNA fragmentation in MG63 cells upon treatment of DOX-MSNCaP@PLGA-collagen for 12 hours (I: PLGA-collagen at pH 7.4, II: DOX-MSNCaP@PLGA-collagen at pH 7.4, III: DOX-MSNCaP@PLGA-collagen at pH 6.5) (D).

Article Snippet: Different types of cells were utilized in this work, including human bone marrow-derived mesenchymal stem cells (MSCs, passage 4) obtained from LONZA (MD, USA), and the human osteosarcoma cell line (MG63) purchased from Procell Life Science & Technology Co., Ltd (China; Catalog No. CL-0157).

Techniques: Construct, Cell Culture, Staining, Incubation, Fluorescence, DNA Laddering

Journal: RSC Advances

Article Title: Replicating the post-chemotherapy tumor microenvironment via biomimetic scaffolds to regulate MSC differentiation

doi: 10.1039/d6ra01031h

Figure Lengend Snippet: BrdU staining of MG63 upon treatment of DOX-MSNCaP@PLGA-collagen at pH 7.4 or pH 6.5. Scale bar: 50 µm.

Article Snippet: Different types of cells were utilized in this work, including human bone marrow-derived mesenchymal stem cells (MSCs, passage 4) obtained from LONZA (MD, USA), and the human osteosarcoma cell line (MG63) purchased from Procell Life Science & Technology Co., Ltd (China; Catalog No. CL-0157).

Techniques: BrdU Staining

Journal: Frontiers in Immunology

Article Title: Development and evaluation of an inhalable nanoemulsion system for enhancing NK cell function against osteosarcoma pulmonary metastases

doi: 10.3389/fimmu.2026.1772375

Figure Lengend Snippet: SIS3-VAP–DAC nanoemulsion enhances in vitro NK-92 cell-mediated cytotoxicity of osteosarcoma in the presence of TGF-β. Fold-change in MG63-GFP cell count measured by IncuCyte over 48 h following co-incubation with irradiated NK-92 cells (E:T 5:1) in media supplemented with 5 ng/mL TGF-β and 50% (v/v) NE1 (blank), NE2 (SIS3), NE3 (VAP–DAC), or NE4 (SIS3-VAP–DAC) nanoemulsions.

Article Snippet: Recombinant human (rh)IL-2 and rhIL-15 were obtained from the Biological Resources Branch (National Cancer Institute, Frederick, MD) and recombinant murine IL-15 was purchased from R&D Systems (Minneapolis, MN). hSAEC primary small airway epithelial cells (Cat #PCS-301-010), NK-92 human NK cell lymphoma (Cat #CRL-2407), MG63 human osteosarcoma (Cat #CRL-1427), and K7M2 murine osteosarcoma (Cat #CRL-2836) cell lines were all obtained from ATCC (Manassas, VA).

Techniques: In Vitro, Cell Characterization, Incubation, Irradiation

Journal: Frontiers in Immunology

Article Title: Development and evaluation of an inhalable nanoemulsion system for enhancing NK cell function against osteosarcoma pulmonary metastases

doi: 10.3389/fimmu.2026.1772375

Figure Lengend Snippet: Combination SIS3-VAP–DAC nanoemulsion with adoptive NK-92 cell therapy reduces pulmonary osteosarcoma metastases in vivo without systemic toxicity. (A) Representative bioluminescence images of mice from each treatment group at week 1 of dosing. (B) Chest-region bioluminescence ROI values at week 1 across treatment groups. Box and whisker plots display quantitative ROI measurements from the chest area of individual mice, with the middle line indicating the median value. Data represent pulmonary tumor burden after one week of treatment. Whiskers represent data within 1.5 times the interquartile range. (C) Representative bioluminescence images of mice from each treatment group at week 2 of dosing. (D) Chest-region bioluminescence ROI values at week 2 across treatment groups. Box and whisker plots display quantitative ROI measurements from the chest area of individual mice, with the middle line indicating the median value. Data represent pulmonary tumor burden after two weeks of treatment. Whiskers represent data within 1.5 times the interquartile range. (E) Representative bioluminescence images of mice from each treatment group at week 3 of dosing. (F) Chest-region bioluminescence ROI values at week 3 across treatment groups. Box and whisker plots display quantitative ROI measurements from the chest area of individual mice, with the middle line indicating the median value. Data represent pulmonary tumor burden after three weeks of treatment. Whiskers represent data within 1.5 times the interquartile range. At weeks 2 and 3 (D, F) , asterisks denote statistically significant differences between NE7 and the control group by Kruskal–Wallis non−parametric analysis of variance followed by Dunn’s post hoc test (*: p < 0.05, Bonferroni corrected). No significant differences were detected at week 1 (B) . (G) Percentage change in mean body weight over time for control and nanoemulsion-treated mice (NE5-NE7) following MG63 cancer cell injection. Error bars represent ± SD of the percentage changes from baseline at each timepoint. (H) Summed clinical scores in control and nanoemulsion-treated mice (NE5-NE7) over 49 days after MG63 cancer cell injection. Points at zero indicate no observable adverse clinical signs.

Article Snippet: Recombinant human (rh)IL-2 and rhIL-15 were obtained from the Biological Resources Branch (National Cancer Institute, Frederick, MD) and recombinant murine IL-15 was purchased from R&D Systems (Minneapolis, MN). hSAEC primary small airway epithelial cells (Cat #PCS-301-010), NK-92 human NK cell lymphoma (Cat #CRL-2407), MG63 human osteosarcoma (Cat #CRL-1427), and K7M2 murine osteosarcoma (Cat #CRL-2836) cell lines were all obtained from ATCC (Manassas, VA).

Techniques: In Vivo, Whisker Assay, Control, Injection